[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-378719-105":59,"doc-detail-378719-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mucopenetrating-janus-nanoparticles-for-field-coverage-oral-cancer-chemoprevention","Mucopenetrating Janus Nanoparticles For Field-Coverage Oral Cancer Chemoprevention","","Oral squamous cell carcinoma (OSCC) causes severe morbidity and mortality, yet chemoprevention has been constrained by a lack of broadly applicable local delivery systems. This study engineers Janus nanoparticles (JNP) combining chitosan mucoadhesion with a poly(lactide-co-glycolide) release compartment to avoid rapid mucus clearance while enabling stable loading and controlled delivery of the IL-6 receptor antagonist tocilizumab. Results show effective mucopenetration, retained tocilizumab activity, and strong tumor growth inhibition in an aggressive OSCC xenograft model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mucopenetrating-janus-nanoparticles-for-field-coverage-oral-cancer-chemoprevention/378719/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mucopenetrating-janus-nanoparticles-for-field-coverage-oral-cancer-chemoprevention/378719.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study target in oral cancer chemoprevention?","Question",{"text":112,"@type":113},"The study addresses OSCC chemoprevention limitations caused by insufficient availability of broadly applicable local delivery systems and poor achievement of therapeutically relevant intraoral levels from systemic delivery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are the Janus nanoparticles (JNP) designed in this work?",{"text":117,"@type":113},"JNP are engineered with a first cationic chitosan compartment for dual mucoadhesive properties and a second hydrophobic poly(lactide-co-glycolide) release compartment for controlled delivery of tocilizumab.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes are reported for the tocilizumab-loaded JNP?",{"text":121,"@type":113},"The nanoparticles show controlled release with retained biological activity, effective internalization by oral keratinocytes, strong mucopenetration in oral mucosal explants, and high xenograft inhibition in an OSCC model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},378719,1790274262,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Pharmaceutical Research (2023) 40:749–764  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1)1095-022-03465-x  \nORIGINAL RESEARCH ARTICLE  \nMucopenetrating Janus Nanoparticles For Field‑Coverage Oral Cancer Chemoprevention  \nNahal Habibi1 · Caroline Bissonnette2,3 · Ping Pei2 · Daren Wang2 · Albert Chang1 · Jeffery E. Raymond1 · Joerg Lahann1 · Susan R. Mallery2,4  \nReceived: 2 August 2022 / Accepted: 18 December 2022 / Published online: 12 January 2023 © The Author(s) 2022  \nAbstract  \nIntroduction Oral squamous cell carcinoma (OSCC), is associated with high morbidity and mortality. Preemptive interventions have been postulated to provide superior therapeutic options, but their implementation has been restricted by the availability of broadly applicable local delivery systems.  \nMethods We address this challenge by engineering a delivery vehicle, Janus nanoparticles (JNP), that combine the dual mucoadhesive properties of a first cationic chitosan compartment with a second hydrophobic poly(lactide-co-glycolide) release compartment. JNP are designed to avoid rapid mucus clearance while ensuring stable loading and controlled release of the IL-6 receptor antagonist, tocilizumab (TCZ) .  \nResults The JNP featured defined and monodispersed sizes with an average diameter of 327 nm and a PDI of 0.245, high circularities above 0.90 and supported controlled release of TCZ and effective internalization by oral keratinocytes. TCZ released from JNP retained its biological activity and effectively reduced both, soluble and membrane-bound IL-6Rα (71% and 50%) . In full-thickness oral mucosal explants, 76% of the JNP breached the stratum corneum and in 41% were observed in the basal cell layer indicating excellent mucopenetrating properties. When tested in an aggressive OSCC xenograft model, TCZ-loaded JNP showed high levels of xenograft inhibition and outperformed all control groups with respect to inhibition of tumor cell proliferation, reduction in tumor size and reduced expression of the proto-oncogene ERG.  \nConclusion By combining critically required, yet orthogonal properties within the same nanoparticle design, the JNP in this study, demonstrate promise as precision delivery platforms for intraoral field-coverage chemoprevention, a vastly underresearched area of high clinical importance.  \nKeywords chemoprevention · controlled-release preparations · nanoparticle drug delivery system · oral cancer · tocilizumab  \nIntroduction  \nNanoparticles have transformed therapeutic delivery and enabled novel treatment modalities for cancer treatment. Oral cancer is a highly debilitating disease that dramatically  \nNahal Habibi and Caroline Bissonnette contributed equally.  \n* Joerg Lahann [lahann@umich.edu](lahann@umich.edu)  \n* Susan R. Mallery [mallery.1@osu.edu](mallery.1@osu.edu)  \n1 Biointerfaces Institute, Departments of Chemical Engineering, Material Science and Engineering, Biomedical Engineering, and Macromolecular Science and Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA  \nimpacts the lives of patients. Notably, oral squamous cell carcinoma (OSCC) is among the most challenging-to-treat human cancers. Clinical issues are elevated by the insidious nature of its early disease and the reliance upon radical surgery as the primary treatment modality [1, 2] . Even if patients achieve a surgical cure, they are still destined to suffer significant morbidity due to loss of vital facial structures  \n2 Division of Oral Maxillofacial Pathology, College of Dentistry, The Ohio State University, 305 W. 12th Ave, Columbus, OH 43210, USA  \n3 Department of Stomatology, Faculty of Dentistry, University of Montreal, Montreal, QC, Canada  \n4 The Ohio State University Comprehensive Cancer, 460  \nW. 10th Avenue, Columbus, OH 43210, USA  \nessential for eating, speaking and esthetics. Similar to many carcinomas, OSCC does not occur de novo, but arises from a precursor surface epithelial lesion termed oral intraepithelial ","cbCaio8PqKDyTXuL","https://ap.wps.com/l/cbCaio8PqKDyTXuL","pdf",3252834,16,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What problem does the study target in oral cancer chemoprevention?\",\"answer\":\"The study addresses OSCC chemoprevention limitations caused by insufficient availability of broadly applicable local delivery systems and poor achievement of therapeutically relevant intraoral levels from systemic delivery.\"},{\"question\":\"How are the Janus nanoparticles (JNP) designed in this work?\",\"answer\":\"JNP are engineered with a first cationic chitosan compartment for dual mucoadhesive properties and a second hydrophobic poly(lactide-co-glycolide) release compartment for controlled delivery of tocilizumab.\"},{\"question\":\"What outcomes are reported for the tocilizumab-loaded JNP?\",\"answer\":\"The nanoparticles show controlled release with retained biological activity, effective internalization by oral keratinocytes, strong mucopenetration in oral mucosal explants, and high xenograft inhibition in an OSCC model.\"}]","Mucopenetrating Janus Nanoparticles For Field-Coverage Oral Cancer Chemoprevention | PDF",1790232079]